European Biotech Acquisition Corp. Warrant
EBACW
EBACW was delisted on the 2nd of March, 2023.
32 hedge funds and large institutions have $1.16M invested in European Biotech Acquisition Corp. Warrant in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
35% more capital invested
Capital invested by funds: $858K → $1.16M (+$301K)
10% more funds holding
Funds holding: 29 → 32 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$10.1K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$7.47K |
| 3 |
MTCM
Mint Tower Capital Management
Amsterdam,
Netherlands
|
+$6.71K |
| 4 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$2.77K |
| 5 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
+$2.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Difesa Capital Management
New York
|
-$1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$121 |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
26
Atalaya Capital Management
New York
| $3.33K | – | – | – |
|
|
VI
27
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $3K | – | – | – |
|
|
OAC
28
OMERS Administration Corp
Toronto,
Ontario, Canada
| $2.92K | – | – | – |
|
|
CCA
29
Castle Creek Arbitrage
Avon,
Colorado
| $2.71K | +$2.15K | +10,681 | New |
|
|
AA
30
Ancora Advisors
Cleveland,
Ohio
| $1K | – | – | – |
|
|
ETH
31
Exos TFP Holdings
New York
| $326 | +$49 | +244 | +29% |
|
|
32
UBS Group
Zurich,
Switzerland
| $90 | -$121 | -600 | -67% |
|
|
DCM
33
Difesa Capital Management
New York
| – | -$1K | -14,159 | Closed |
|
EBACW Hedge Fund Activity: Q4 2022 in Review
32 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Warrant (EBACW) for Q4 2022, worth a combined $1.16M — up 35% from $858K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EBACW positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Meteora Capital, opening a new position worth an estimated $10.1K. The largest seller was Difesa Capital Management, exiting entirely with an estimated $1K sold.
- 32 institutional investors held European Biotech Acquisition Corp. Warrant (EBACW) as of Q4 2022, up from 29 in Q3 2022.
- Funds reported $1.16M of European Biotech Acquisition Corp. Warrant stock for Q4 2022, up 35% quarter-over-quarter.
- 5 funds opened new European Biotech Acquisition Corp. Warrant positions in Q4 2022 and 2 closed out, a net change of +3 holders.
- The largest European Biotech Acquisition Corp. Warrant buyer in Q4 2022 was Meteora Capital, an estimated $10.1K added.
- The largest European Biotech Acquisition Corp. Warrant seller in Q4 2022 was Difesa Capital Management, an estimated $1K sold.
Based on aggregated 13F filings for Q4 2022.